ArticleBMC cancer2025
Age-related differences in adjuvant chemotherapy use and outcomes in stage II colon cancer: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic impact of low skeletal muscle mass in stage I-III colon cancer: A retrospective study.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile the benefit of adjuvant chemotherapy in stage II colon cancer remains uncertain, less is known about how age influences its use and associated outcomes in this population.
methodRetrospective cohort study. Patients who underwent radical colon cancer surgery, from 2013 to 2018, divided into age groups; 18–49 (young), 50–64 (middle aged), and 65–75 (older) years. To compare the adjuvant therapy and survival of patients with stage II colon cancer in different age groups.
resultsAt baseline, the young showed fewer comorbidities (16.1% vs. 37.2% vs. 54.9%, p < 0.001) than the middle-aged and older groups, and the pathological results showed worse differentiation types (25.8% vs. 7.4% vs. 6.1%, p = 0.017), but more microsatellite instability-high status (21.51% vs. 9.10% vs.10.57%, p = 0.005). Among patients with stage II colon cancer, young and middle-aged patients were more likely to receive adjuvant chemotherapy [odds ratio (OR): 4.196 (95% confidence interval (CI), 2.247–7.835); 2.610 (95% CI, 1.743–3.910)]. Among patients receiving adjuvant chemotherapy, young and middle-aged patients were more likely to receive multi-drug chemotherapy than older patients [OR: 3.181 (95% CI, 1.255–8.064); 2.642 (95% CI, 1.386–5.036)]. There was no significant difference in survival among patients with stage II colon cancer who underwent surgery alone or surgery combined with adjuvant chemotherapy among different age groups.
conclusionAmong patients with stage II colon cancer, young and middle-aged patients were more likely to receive adjuvant chemotherapy and more aggressive chemotherapy regimens, but this was not associated with survival benefits compared to the older age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.